Checkpoint Genes at the Cancer Side of the Immunological Synapse in Bladder Cancer

Immune checkpoint inhibitors have revolutionized cancer therapy, but not all cancers respond to the currently available drugs, and even within cancers considered responsive to such modality, response rates range between 15 and 40%, depending on the cancer type, the line of treatment, and yet unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobosz, Paula, Stempor, Przemysław A., Roszik, Jason, Herman, Amir, Layani, Adi, Berger, Raanan, Avni, Dror, Sidi, Yechezkel, Leibowitz-Amit, Raya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931203/
https://www.ncbi.nlm.nih.gov/pubmed/31869744
http://dx.doi.org/10.1016/j.tranon.2019.10.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931203/
https://www.ncbi.nlm.nih.gov/pubmed/31869744
http://dx.doi.org/10.1016/j.tranon.2019.10.018

Ejemplares similares